Aarti Drugs Limited — Call Transcript 2025

Jan 23, 2025

==> picture [516 x 97] intentionally omitted <==

Ref: ADL/SE/2024-25/116 January 23, 2025

To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Phiroze Jeejeebhoy Towers, Limited, Dalal Street, “Exchange Plaza”, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400051 NSE SYMBOL: AARTIDRUGS BSE CODE – 524348

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Intimation of Conference Call

This is to inform you that Quarterly Earning Conference Call for the Investors and Analysts have been scheduled on January 30, 2025 at 11:00 A.M. IST to discuss the Company’s financial performance for the Quarter ended December 31, 2024.

Please find attached herewith invitation for the same.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH Digitally signed by RUSHIKESH VIVEK DEOLE VIVEK DEOLE Date: 2025.01.23 19:53:07 +05'30'

RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M.No.: F12932

==> picture [475 x 24] intentionally omitted <==

==> picture [392 x 68] intentionally omitted <==

Q3 & 9M FY25 Earnings Conference Call

DATE & TIME 30[th] January 2025 (Thursday) 11:00 am, IST (HK/Singapore 1:30 pm, UK 5:30 am, USA 12:30 am EST)

PARTICIPANTS

• Mr. Harshit Savla – Jt. Managing Director

Mr. Harit Shah – Whole time Director

• Mr. Adhish Patil – Chief Finance Officer & Chief Operating Officer Mr. Vishwa Savla – Managing Director, Pinnacle Life Science Private Limited

PRE REGISTRATION LINK – CLICK HERE

CONFERENCE DIAL IN DETAILS

INDIA +91 22 6280 1309 / +91 22 7115 8210 UNITED STATES 1 866 746 2133 UNITED KINGDOM 0 808 101 1573 SINGAPORE 800 101 2045 HONG KONG 800 964 448

RSVP:

Strategic Growth Advisors Pvt. Ltd.

Mr. Deven Dhruva Contact: +91 98333 73300